Financhill
Sell
49

CHE Quote, Financials, Valuation and Earnings

Last price:
$581.50
Seasonality move :
1.79%
Day range:
$574.28 - $583.80
52-week range:
$512.12 - $623.61
Dividend yield:
0.33%
P/E ratio:
28.15x
P/S ratio:
3.49x
P/B ratio:
7.16x
Volume:
111.8K
Avg. volume:
134.6K
1-year change:
2.21%
Market cap:
$8.5B
Revenue:
$2.4B
EPS (TTM):
$20.53

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CHE
Chemed
$641.8M $5.55 9.18% 29.89% $677.33
ADUS
Addus HomeCare
$339.9M $1.33 20.51% 33.48% $136.10
AMED
Amedisys
$596.5M $1.11 4.11% 40.38% $96.86
HCAT
Health Catalyst
$79.2M $0.00 6.49% -99.77% $8.09
OPCH
Option Care Health
$1.3B $0.35 10.25% 32.25% $38.56
OPRX
OptimizeRx
$18.7M -$0.12 18.36% -91.67% $15.08
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CHE
Chemed
$578.02 $677.33 $8.5B 28.15x $0.50 0.33% 3.49x
ADUS
Addus HomeCare
$111.09 $136.10 $2B 25.08x $0.00 0% 1.64x
AMED
Amedisys
$94.12 $96.86 $3.1B 34.73x $0.00 0% 1.32x
HCAT
Health Catalyst
$3.90 $8.09 $271.4M -- $0.00 0% 0.79x
OPCH
Option Care Health
$33.09 $38.56 $5.4B 26.69x $0.00 0% 1.09x
OPRX
OptimizeRx
$12.20 $15.08 $225.6M -- $0.00 0% 2.37x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CHE
Chemed
-- 0.460 -- 1.58x
ADUS
Addus HomeCare
16.64% 0.970 10.92% 1.61x
AMED
Amedisys
23.6% -0.140 12.01% 1.23x
HCAT
Health Catalyst
50.4% 1.824 121.45% 1.20x
OPCH
Option Care Health
45.12% 0.749 19.41% 0.91x
OPRX
OptimizeRx
21.84% -2.555 20.29% 2.69x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CHE
Chemed
$216.4M $94.8M 26.04% 26.04% 14.84% $19.5M
ADUS
Addus HomeCare
$107.7M $30.5M 7.78% 8.66% 9.18% $17.1M
AMED
Amedisys
$260.7M $60.1M 5.72% 7.55% 16.41% -$5.1M
HCAT
Health Catalyst
$36.2M -$20.2M -10.75% -20.06% -20.41% -$5.1M
OPCH
Option Care Health
$263.1M $79.2M 8.53% 15.22% 5.76% -$16.6M
OPRX
OptimizeRx
$13.3M -$2.1M -10.09% -13.03% -9.06% $3.8M

Chemed vs. Competitors

  • Which has Higher Returns CHE or ADUS?

    Addus HomeCare has a net margin of 11.09% compared to Chemed's net margin of 6.29%. Chemed's return on equity of 26.04% beat Addus HomeCare's return on equity of 8.66%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHE
    Chemed
    33.45% $4.86 $1.2B
    ADUS
    Addus HomeCare
    31.89% $1.16 $1.2B
  • What do Analysts Say About CHE or ADUS?

    Chemed has a consensus price target of $677.33, signalling upside risk potential of 17.18%. On the other hand Addus HomeCare has an analysts' consensus of $136.10 which suggests that it could grow by 22.51%. Given that Addus HomeCare has higher upside potential than Chemed, analysts believe Addus HomeCare is more attractive than Chemed.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHE
    Chemed
    2 0 0
    ADUS
    Addus HomeCare
    7 0 0
  • Is CHE or ADUS More Risky?

    Chemed has a beta of 0.593, which suggesting that the stock is 40.659% less volatile than S&P 500. In comparison Addus HomeCare has a beta of 0.850, suggesting its less volatile than the S&P 500 by 14.958%.

  • Which is a Better Dividend Stock CHE or ADUS?

    Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.33%. Addus HomeCare offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Addus HomeCare pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHE or ADUS?

    Chemed quarterly revenues are $646.9M, which are larger than Addus HomeCare quarterly revenues of $337.7M. Chemed's net income of $71.8M is higher than Addus HomeCare's net income of $21.2M. Notably, Chemed's price-to-earnings ratio is 28.15x while Addus HomeCare's PE ratio is 25.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.49x versus 1.64x for Addus HomeCare. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHE
    Chemed
    3.49x 28.15x $646.9M $71.8M
    ADUS
    Addus HomeCare
    1.64x 25.08x $337.7M $21.2M
  • Which has Higher Returns CHE or AMED?

    Amedisys has a net margin of 11.09% compared to Chemed's net margin of 10.26%. Chemed's return on equity of 26.04% beat Amedisys's return on equity of 7.55%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHE
    Chemed
    33.45% $4.86 $1.2B
    AMED
    Amedisys
    43.84% $1.84 $1.6B
  • What do Analysts Say About CHE or AMED?

    Chemed has a consensus price target of $677.33, signalling upside risk potential of 17.18%. On the other hand Amedisys has an analysts' consensus of $96.86 which suggests that it could grow by 2.91%. Given that Chemed has higher upside potential than Amedisys, analysts believe Chemed is more attractive than Amedisys.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHE
    Chemed
    2 0 0
    AMED
    Amedisys
    0 9 1
  • Is CHE or AMED More Risky?

    Chemed has a beta of 0.593, which suggesting that the stock is 40.659% less volatile than S&P 500. In comparison Amedisys has a beta of 0.964, suggesting its less volatile than the S&P 500 by 3.612%.

  • Which is a Better Dividend Stock CHE or AMED?

    Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.33%. Amedisys offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Amedisys pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHE or AMED?

    Chemed quarterly revenues are $646.9M, which are larger than Amedisys quarterly revenues of $594.8M. Chemed's net income of $71.8M is higher than Amedisys's net income of $61M. Notably, Chemed's price-to-earnings ratio is 28.15x while Amedisys's PE ratio is 34.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.49x versus 1.32x for Amedisys. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHE
    Chemed
    3.49x 28.15x $646.9M $71.8M
    AMED
    Amedisys
    1.32x 34.73x $594.8M $61M
  • Which has Higher Returns CHE or HCAT?

    Health Catalyst has a net margin of 11.09% compared to Chemed's net margin of -29.9%. Chemed's return on equity of 26.04% beat Health Catalyst's return on equity of -20.06%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHE
    Chemed
    33.45% $4.86 $1.2B
    HCAT
    Health Catalyst
    45.63% -$0.35 $759.7M
  • What do Analysts Say About CHE or HCAT?

    Chemed has a consensus price target of $677.33, signalling upside risk potential of 17.18%. On the other hand Health Catalyst has an analysts' consensus of $8.09 which suggests that it could grow by 107.46%. Given that Health Catalyst has higher upside potential than Chemed, analysts believe Health Catalyst is more attractive than Chemed.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHE
    Chemed
    2 0 0
    HCAT
    Health Catalyst
    7 4 0
  • Is CHE or HCAT More Risky?

    Chemed has a beta of 0.593, which suggesting that the stock is 40.659% less volatile than S&P 500. In comparison Health Catalyst has a beta of 1.559, suggesting its more volatile than the S&P 500 by 55.873%.

  • Which is a Better Dividend Stock CHE or HCAT?

    Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.33%. Health Catalyst offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Health Catalyst pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHE or HCAT?

    Chemed quarterly revenues are $646.9M, which are larger than Health Catalyst quarterly revenues of $79.4M. Chemed's net income of $71.8M is higher than Health Catalyst's net income of -$23.7M. Notably, Chemed's price-to-earnings ratio is 28.15x while Health Catalyst's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.49x versus 0.79x for Health Catalyst. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHE
    Chemed
    3.49x 28.15x $646.9M $71.8M
    HCAT
    Health Catalyst
    0.79x -- $79.4M -$23.7M
  • Which has Higher Returns CHE or OPCH?

    Option Care Health has a net margin of 11.09% compared to Chemed's net margin of 3.51%. Chemed's return on equity of 26.04% beat Option Care Health's return on equity of 15.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHE
    Chemed
    33.45% $4.86 $1.2B
    OPCH
    Option Care Health
    19.73% $0.28 $2.5B
  • What do Analysts Say About CHE or OPCH?

    Chemed has a consensus price target of $677.33, signalling upside risk potential of 17.18%. On the other hand Option Care Health has an analysts' consensus of $38.56 which suggests that it could grow by 16.52%. Given that Chemed has higher upside potential than Option Care Health, analysts believe Chemed is more attractive than Option Care Health.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHE
    Chemed
    2 0 0
    OPCH
    Option Care Health
    6 1 0
  • Is CHE or OPCH More Risky?

    Chemed has a beta of 0.593, which suggesting that the stock is 40.659% less volatile than S&P 500. In comparison Option Care Health has a beta of 0.763, suggesting its less volatile than the S&P 500 by 23.686%.

  • Which is a Better Dividend Stock CHE or OPCH?

    Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.33%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHE or OPCH?

    Chemed quarterly revenues are $646.9M, which are smaller than Option Care Health quarterly revenues of $1.3B. Chemed's net income of $71.8M is higher than Option Care Health's net income of $46.7M. Notably, Chemed's price-to-earnings ratio is 28.15x while Option Care Health's PE ratio is 26.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.49x versus 1.09x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHE
    Chemed
    3.49x 28.15x $646.9M $71.8M
    OPCH
    Option Care Health
    1.09x 26.69x $1.3B $46.7M
  • Which has Higher Returns CHE or OPRX?

    OptimizeRx has a net margin of 11.09% compared to Chemed's net margin of -10.03%. Chemed's return on equity of 26.04% beat OptimizeRx's return on equity of -13.03%.

    Company Gross Margin Earnings Per Share Invested Capital
    CHE
    Chemed
    33.45% $4.86 $1.2B
    OPRX
    OptimizeRx
    60.85% -$0.12 $148.8M
  • What do Analysts Say About CHE or OPRX?

    Chemed has a consensus price target of $677.33, signalling upside risk potential of 17.18%. On the other hand OptimizeRx has an analysts' consensus of $15.08 which suggests that it could grow by 23.63%. Given that OptimizeRx has higher upside potential than Chemed, analysts believe OptimizeRx is more attractive than Chemed.

    Company Buy Ratings Hold Ratings Sell Ratings
    CHE
    Chemed
    2 0 0
    OPRX
    OptimizeRx
    4 1 0
  • Is CHE or OPRX More Risky?

    Chemed has a beta of 0.593, which suggesting that the stock is 40.659% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.283, suggesting its more volatile than the S&P 500 by 28.349%.

  • Which is a Better Dividend Stock CHE or OPRX?

    Chemed has a quarterly dividend of $0.50 per share corresponding to a yield of 0.33%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Chemed pays 8.97% of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios CHE or OPRX?

    Chemed quarterly revenues are $646.9M, which are larger than OptimizeRx quarterly revenues of $21.9M. Chemed's net income of $71.8M is higher than OptimizeRx's net income of -$2.2M. Notably, Chemed's price-to-earnings ratio is 28.15x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Chemed is 3.49x versus 2.37x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CHE
    Chemed
    3.49x 28.15x $646.9M $71.8M
    OPRX
    OptimizeRx
    2.37x -- $21.9M -$2.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Ginkgo Bioworks Stock a Good Buy?
Is Ginkgo Bioworks Stock a Good Buy?

Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…

Why Mobileye Might Be Wall Street’s Next Big Surprise
Why Mobileye Might Be Wall Street’s Next Big Surprise

The trend to automate vehicles started long ago when adding…

Why Is Rigetti Stock Going Up?
Why Is Rigetti Stock Going Up?

Quantum computing firm Rigetti Computing (NASDAQ:RGTI) has been one of…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
71
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
99
SOC alert for May 20

Sable Offshore [SOC] is down 0.79% over the past day.

Buy
52
RGC alert for May 20

Regencell Bioscience Holdings [RGC] is up 31.16% over the past day.

Sell
40
GWLIF alert for May 20

Great-West Lifeco [GWLIF] is up 13.42% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock